Elysium Basis review: is it worth it?

What is Elysium Basis and who makes it?

Basis is the flagship product of Elysium Health, a New York–based supplement company founded in 2014. Its origin story is unusually credentialed for the supplement aisle: Elysium was co-founded by Leonard Guarente, an MIT biologist who is one of the most cited researchers in the biology of aging and a pioneer of sirtuin science. The company also maintains a scientific advisory board that has included multiple Nobel laureates. This academic pedigree is central to Basis's marketing and is a real differentiator — most NAD+ products have no comparable scientific lineage.

Basis itself is a "cellular health" or "healthy aging" supplement. Each serving (two capsules) delivers 250 mg of nicotinamide riboside chloride (NR) and 50 mg of pterostilbene (PT). NR is a precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme involved in hundreds of metabolic reactions, mitochondrial energy production, and DNA repair. NAD+ levels decline with age, and the core thesis behind Basis — and the entire NAD+ supplement category — is that restoring NAD+ might counteract some aspects of aging.

One important piece of context: Basis is a dietary supplement, not an FDA-approved drug. It is not approved to treat, cure, or prevent any disease, and the U.S. Food and Drug Administration does not evaluate supplements for efficacy before they reach the market. The NR ingredient (branded Niagen, originally supplied by ChromaDex) has been the subject of FDA new dietary ingredient (NDI) notifications and is "generally recognized as safe" (GRAS) for certain uses, but GRAS status speaks to safety, not to anti-aging benefits.

How does Basis work?

The proposed mechanism is straightforward on paper. NAD+ is consumed by enzymes such as sirtuins (which Guarente's lab helped characterize), PARPs (involved in DNA repair), and CD38. Because cells can't efficiently absorb NAD+ directly, supplements instead provide precursors the body converts into NAD+. Nicotinamide riboside is one such precursor; it enters cells and is phosphorylated into nicotinamide mononucleotide (NMN) and then into NAD+.

Pterostilbene, the second ingredient, is a polyphenol chemically related to resveratrol and found naturally in blueberries. Elysium's rationale is that pterostilbene is a sirtuin-activating, antioxidant compound that complements raised NAD+ levels. It is worth being candid here: the human evidence specifically supporting pterostilbene's contribution to any longevity outcome is thin, and most of the measurable action in Basis comes from the NR raising NAD+.

The key qualifier is the gap between mechanism and outcome. Raising NAD+ is a *biomarker* change. Whether higher NAD+ in healthy people produces meaningful downstream benefits — more energy, better metabolic health, slower biological aging — is the open question that the mechanism alone cannot answer.

What does the evidence actually show?

Basis is better-studied than most supplements, but the evidence is narrower than the marketing implies.

The pivotal Basis trial

The headline study is a randomized, double-blind, placebo-controlled trial of 120 healthy adults aged 60–80, published in *npj Aging and Mechanisms of Disease* (Dellinger et al., 2017; PMID 29184669). Over eight weeks, participants took either the recommended dose (250 mg NR + 50 mg PT), double that dose, or placebo. The findings:

• The recommended dose raised whole-blood NAD+ by about 40% over baseline, sustained through the eight weeks.
• The double dose raised NAD+ by roughly 90% at four weeks, though this larger increase was not as well sustained (declining toward ~55% by week eight).
• The placebo group showed no change.
• No serious adverse events were reported; side effects were generally mild.

This is a genuinely positive, well-designed result — but only for the biomarker. The trial demonstrated that Basis *raises NAD+ safely*. It was not powered to show, and did not show, clinical benefits such as improved physical function, cognition, or aging markers. A crucial disclosure: the trial was funded by Elysium Health and several authors were Elysium employees with equity stakes, though the data collection itself was conducted by an independent contract research organization (KGK Synergize, in London, Ontario).

What independent NR research shows

Looking beyond Elysium's own data is essential. Independent trials of nicotinamide riboside consistently confirm the *biomarker* effect: in a randomized crossover trial in healthy middle-aged and older adults, chronic NR was well tolerated and effectively raised NAD+ (Martens et al., *Nature Communications*, 2018; PMID 29599478). Larger dose-ranging work (Conze et al., 2019) found NR raised NAD+ within two weeks and kept it elevated.

But on *clinical* endpoints the picture is sobering. A 2023 critical review in *Science Advances* ("What is really known about the effects of nicotinamide riboside supplementation in humans") analyzed roughly two dozen human trials and concluded that, collectively, oral NR has shown few clinically relevant effects, and that the literature tends to exaggerate the importance and robustness of reported findings. In plainer terms: NR reliably moves a lab number, but the human payoff for healthy people remains unproven.

The honest bottom line on evidence

There is, as of 2026, no published human trial demonstrating that Basis (or NR generally) extends lifespan, slows biological aging, or produces a reliable functional benefit in healthy adults. The strongest, most defensible claim Elysium can make is the one its own trial supports: Basis raises NAD+. Everything beyond that — the implied promise of "supporting healthy aging at the cellular level" — is mechanistic hope, not demonstrated outcome.

Does Basis have any proven side effects or safety concerns?

On safety, Basis looks reassuring. Across the Elysium trial and independent NR studies, the supplement has been well tolerated, with no serious adverse events attributable to it. Reported side effects are typically mild and may include nausea, gastrointestinal upset, headache, or fatigue, more often at higher doses. NR has been tested at doses far above what Basis provides (up to 1,000–2,000 mg daily in research settings) without evidence of toxicity.

That said, important caveats apply:

• Long-term safety data are limited. Most trials run weeks to a few months. The effects of taking Basis for years — which is how it's actually marketed and used — have not been rigorously characterized.
• Cancer-biology uncertainty. Because NAD+ fuels cellular metabolism and proliferation, some researchers have raised theoretical questions about NAD+ boosters in people with, or at risk of, certain cancers. This is unresolved, not a demonstrated danger, but it warrants caution and a conversation with an oncologist for anyone with a cancer history.
• Pregnancy, breastfeeding, and medications. Safety in pregnancy and breastfeeding is not established. Pterostilbene may theoretically interact with blood thinners or affect lipid/glucose measures. Anyone on prescription medication should check with a clinician.

As with all supplements, Basis is not third-party verified by USP or NSF, so purity and label accuracy rely on the manufacturer's own quality controls rather than independent certification — a relevant downside for a product taken daily over years.

How do you take Basis, and what does it cost?

Dosing is simple: two capsules once daily, in the morning, with or without food. There is no titration schedule and no special timing requirement.

Pricing (2026): Basis uses a subscription-first model.

• One-time purchase: about $60 for a 30-day supply.
• Monthly subscription: about $50/month.
• 6-month prepaid plan: roughly $45/month.
• 12-month prepaid plan: roughly $40/month (the lowest per-month price).

At $40–$50 per month, Basis costs $480–$600 per year. That is expensive for a supplement whose only proven effect is raising a blood biomarker. The value question is unavoidable: you are paying a premium largely for the brand's scientific credibility and a clean, single-purpose formula, not for demonstrated health outcomes.

How does Basis compare to other NAD+ supplements?

The NAD+ category has grown crowded, and Basis is no longer the only credentialed option.

• Versus generic NR/Niagen products: Many competitors sell nicotinamide riboside (often the same Niagen ingredient) for less, sometimes without pterostilbene. If your goal is simply to raise NAD+ at lower cost, a standalone NR product may deliver a similar biomarker effect for less money. Basis's distinguishing feature is the added pterostilbene and Elysium's research program — not a proven superiority in outcomes.
• Versus NMN supplements: NMN (nicotinamide mononucleotide) is a competing precursor with its own enthusiast following. NMN's U.S. regulatory status was contested for several years: in late 2022 the FDA took the position that NMN was excluded from the dietary-supplement definition because it had been investigated as a drug. In September 2025, however, the FDA reversed that position and confirmed that NMN is not excluded and may lawfully be sold as a dietary supplement. As of 2026, both NR and NMN have a path to lawful supplement status, so this is no longer a clear differentiator in Basis's favor — though NR remains the more extensively studied of the two in published human trials.
• Versus niacin/nicotinamide: Plain niacin and nicotinamide also raise NAD+ and cost almost nothing. They lack the targeted research and tolerability profile (niacin causes flushing) that NR offers, but they illustrate how much of the Basis price reflects branding and formulation rather than a unique biological mechanism.

It's also worth flagging the ChromaDex–Elysium litigation as context. Elysium and its former NR supplier ChromaDex engaged in years of high-profile legal disputes over supply, patents, and trademarks. This is a business and supply-chain story rather than a safety issue, but it has shaped pricing, branding, and ingredient sourcing across the category, and it speaks to the commercial intensity behind these "science-first" products.

Who should consider Basis, and who should skip it?

Basis may make sense for you if you are a healthy adult who wants to proactively raise NAD+, you value Elysium's research-driven approach, you understand you're paying for a biomarker effect rather than a guaranteed benefit, and the $40–$50/month cost is comfortable discretionary spending. Early adopters and "quantified self" enthusiasts who track biomarkers are the natural audience.

You should probably skip Basis if you expect noticeable, felt benefits (most users report nothing dramatic, consistent with the lack of clinical-outcome data), if you're on a tight budget (cheaper NR achieves similar NAD+ elevation), if you're pregnant or breastfeeding, or if you have a cancer history without clearing it with your physician. Anyone hoping Basis will treat a specific medical condition should stop — it is not a treatment for anything.

The bottom line

Elysium Basis is one of the most legitimate, best-researched products in an otherwise hype-saturated category. The science it rests on is real: NR plus pterostilbene reliably and safely raises NAD+ by about 40%, demonstrated in a properly controlled trial (PMID 29184669) and corroborated by independent NR research. The company's scientific pedigree is authentic.

But the honest verdict is that Basis sells a credible mechanism, not a proven outcome. Raising NAD+ is not the same as slowing aging, and as of 2026 there is no human evidence that taking Basis makes healthy people live longer, age slower, or feel measurably better. A major independent review has explicitly cautioned that the field overstates NR's clinical relevance. For roughly $480–$600 a year, you are funding a well-grounded experiment on yourself. If you go in with clear eyes — understanding that you're buying a biomarker shift and a research bet, not a validated longevity benefit — Basis is a defensible, low-risk choice. If you want demonstrated results, the science isn't there yet, for Basis or for any NAD+ supplement.